
Index

A

- AACE. *See* American Association of Clinical Endocrinology (AACE)
AAES. *See* American Association of Endocrine Surgeons (AAES)
Accreditation, thyroid ultrasound, 22–25
ACS. *See* American College of Surgeons (ACS)
Afirma® (Veracyte), 146–148
AHNS. *See* American Head and Neck Society (AHNS)
AJCC. *See* American Joint Commission on Cancer (AJCC)
American Association of Clinical Endocrinology (AACE), 22, 33
American Association of Endocrine Surgeons (AAES), 22
American College of Surgeons (ACS), 22, 60
American Head and Neck Society (AHNS), 22
American Institute of Ultrasound in Medicine (AIUM), 22
American Joint Commission on Cancer (AJCC), 59, 191, 205
American Thyroid Association (ATA) guidelines, 5, 16, 22, 33, 153, 177, 178
AMES (age, metastasis, extent of disease, and size), 205
Anaplastic thyroid cancers (ATC), 195–198, 204, 209
Association of Ultrasound in Medicine (AIUM), 16, 21
ATA guidelines. *See* American Thyroid Association (ATA) guidelines
ATC. *See* Anaplastic thyroid cancers (ATC)
Atypia/follicular lesion of undetermined significance (AFLUS), 3, 8
Atypia of undetermined significance (AUS), 143

B

- BAETS. *See* The British Association of Endocrine and Thyroid Surgeons (BAETS)
B-cell non-Hodgkin lymphoma, 198
Bethesda System for Reporting Thyroid Cytopathology (BSRTC)
bethesda I, 7
bethesda II, 7
bethesda III, 8
bethesda IV, 8–9
bethesda V, 9–10
bethesda VI, 10

- Bilateral vocal fold paralysis, 121–122
etiology of, 110
Body mass index (BMI), 104
The British Association of Endocrine and Thyroid Surgeons (BAETS), 33

C

- Cabozantinib, 211, 221
Calcitonin (CTN), 157
Carcinoembryonic antigen (CEA), 157
C-cell hyperplasia (CCH), 158
Central lymph node dissection, 169
Cimetra®, 117
Cimtra®, 117
Conventional FTC (cFTC), 150
Cricothyroid muscle dysfunction, 32
Cutaneous lichen amyloidosis (CLA), 158
Cytotoxic agents, 206–207

D

- Differentiated thyroid cancers (DTC), 4, 204
Diffuse large B-cell lymphomas (DLBCL), 198
Dysphonia, 109

E

- EBSLN. *See* External branch of the superior laryngeal nerve (EBSLN)
Electronic health records (EHR), 15
Endocrine Certification in Neck Ultrasound (ECNU), 22
The Endocrine Society (TES), 22
External beam radiation therapy (EBRT), 178, 203
External branch of the superior laryngeal nerve (EBSLN), 39–40, 115, 116

F

- Familial MTC (FMTC), 158
Fiberoptic laryngoscopy (FOL), 34
Fine-needle aspiration (FNA)
accuracy of, 143–144
cost-effectiveness, 153–154

- Fine-needle aspiration (FNA) (*cont.*)
 diagnosis, gold standard, 144
 molecular markers
 Afirma[®] (Veracyte), 146–148
 microRNA, 149–150
 mutation/rearrangement panel, 144–146
 next-generation sequencing, 148–149
 rapidly accelerated fibrosarcoma isoform B (BRAF), 144
 surgical decision-making, 151–152
 thyroid follicles, 162
- Fine-needle aspiration biopsy (FNAB), 3, 4, 7, 13, 14, 17, 127
- FNA. *See* Fine-needle aspiration (FNA)
- Follicular neoplasm with oncocytic features (FNOF), 146
- Follicular variant of papillary thyroid cancer (FVPTC), 144
- Frozen section exam (FSE), 7
- G**
- Gelfoam[®], 117
- Graves' disease (GD)
 antithyroid medications, 95–96
 considerations, 99–100
 costs, 100–101
 diagnosis and manifestations, 92–94
 goals of treatment, 94–95
 perioperative period, management strategies in
 levothyroxine, 104
 medications, 102–103
 nerve monitor, 103–104
 potassium iodide, 101–102
 quality of life, 100–101
 radioactive iodine ablation, 96–97
 thyroidectomy, 97–99
 treatment options, 92
- H**
- Halsted radical mastectomy, 169
- Hereditary MTC. *See also* Medullary thyroid carcinoma (MTC)
 clinical evidence, 161
 and familial MTC (FMTC), 158
 prophylactic thyroidectomy, 159–160
- High-volume surgeons, 57–59, 61, 62, 65
- Hodgkin lymphoma, 198
- Hürthle cell thyroid carcinoma (HTC), 204
- Hyaluronic acid (HA), 117
- Hyperparathyroidism (HPTH), 158
- Hyperthyroidism, 91, 101, 102
- Hypoparathyroidism, 75–76
- I**
- Imaging, thyroid cancer
 cross-sectional imaging
 computed tomography (CT), 190–191
 functional imaging, 191
 magnetic resonance imaging (MRI), 191
 imaging costs, 192
 MACIS (metastases, age, completeness of resection, invasion, and size), 192
 neck ultrasound
 laryngeal ultrasonography, 189
 lymph nodes, 186–188
 previous neck surgery, setting of, 188
 primary tumors, 185–186
 ultrasound sonoelastography, 188–189
 preoperative and dynamic staging, 191–192
 radioactive iodine therapy, 190–191
- Indeterminate thyroid nodule, 143, 144
- Intraoperative neuro-monitoring (IONM)
 anatomy
 external branch of the superior laryngeal nerve (EBSLN), 39–40
 larynx, vagal innervation of, 39
 recurrent laryngeal nerve (RLN), 40
 right nonrecurrent laryngeal nerve, 40–42
 superior laryngeal nerve (SLN), 39
 application of, 113
 continuous neuro-monitoring, 44
 cost-effectiveness, 52–53
 definition
 of anatomy, 50–51
 of outcomes, 52
 direct observation, 43
 electromyography, 44
 intraoperative decision-making, 51–52
 limitations, 44
 loss of signal (LOS), 45, 46
 negative predictive capacity of, 42, 43
 outcomes of, 47–50
 pressure monitoring, 44
 surgeon experience, 51
 technique overview, 44–45
 troubleshooting, 45–46
- L**
- Laryngeal examination
 asymptomatic vocal fold paralysis, 32
 feasibility of, 33–34
 larynx *vs.* subjective voice assessment, 30
 postoperative, 33
 preoperative, 32–33
 voice alteration, normal vocal fold mobility, 30–32
- Laryngeal nerves, thyroidectomy, 31. *See also*
 Intraoperative neuro-monitoring (IONM)
- Lenvatinib, 204, 214
- M**
- MACIS (metastasis, age, completeness of resection, invasion, and size), 205
- Maximum phonatory time (MPT), 117
- Medullary thyroid carcinoma (MTC), 204, 209, 221.
See also Hereditary MTC
 genetics, 158–159
 hereditary, 158

oncologic follow-up, 165
 parathyroids, management of, 164
 persistent or recurrent disease, 165–166
 postoperative surveillance, 164–165
 preoperative evaluation, 161–162
 surgical approach, 162–164
 MEN2A. *See* Multiple endocrine neoplasia type 2A (MEN2A)
 MEN2B. *See* Multiple endocrine neoplasia type 2B (MEN2B)
 Micronized Dermis (MD), 117
 Mitogen-activated protein kinase (MAPK) pathway, 144
 Molecular markers
 Afirma® (Veracyte), 146–148
 microRNA, 149–150
 mutation/rearrangement panel, 144–146
 next-generation sequencing, 148–149
 rapidly accelerated fibrosarcoma isoform B (BRAF), 144
 MTC. *See* Medullary thyroid carcinoma (MTC)
 Multiple endocrine neoplasia type 2A (MEN2A), 157–159
 Multiple endocrine neoplasia type 2B (MEN2B), 157–159

N

National Cancer Institute (NCI), 6
 National Surgical Quality Improvement Program (NSQIP), 60
 NCI. *See* National Cancer Institute (NCI)
 Neck lymph node, 184
 Neck mass, 195, 196
 Neck ultrasound
 laryngeal ultrasonography, 189
 lymph nodes, 186–188
 previous neck surgery, setting of, 188
 primary tumors, 185–186
 ultrasound sonoelastography, 188–189
 Negative predictive value (NPV), 146
 Nodular thyroid disease
 epidemiology, 3
 evaluation, 4–6
 management
 bethesda I, 7
 bethesda II, 7
 bethesda III, 8
 bethesda IV, 8–9
 bethesda V, 9–10
 bethesda VI, 10
 Nonsurgical treatment. *See* Targeted therapies

O

Oncocytic FTC (oFTC), 150
 Ophthalmopathy, 93, 94
 Outpatient thyroidectomy
 developing, 68–70
 outcomes, 69
 patient selection, 77
 postoperative central neck hematoma
 incidence and timing, 70–71

 management, 73–75
 prevention, 71–73
 postoperative hypoparathyroidism, 75–76
 pros and cons of, 67–68
 recurrent laryngeal nerve injury, 76
 social concerns, 76–77

P

Papillary thyroid cancer (PTC), 3, 127, 128, 144
 Papillary thyroid microcarcinoma (PTMC)
 active surveillance
 clinical impact of, 135
 with patient, 136–137
 patient selection for, 136
 recommendation, 137–138
 safety and efficacy of, 135–136
 disease outcome, robust predictors of, 138–139
 epidemiology
 epidemic proportions, 127–128
 implications of, 128–129
 optimal surgical management
 adverse effects, 132–133
 radioactive iodine therapy, 133–134
 recurrence rates, 134
 TSH-suppressive thyroid hormone replacement therapy, 134
 outcomes
 natural history of, 129
 risk factors, 130–132
 safety of, 139
 Patient outcomes
 by age
 elderly, 59–61
 pediatrics, 61–63
 by race, 59
 Pattern recognition, thyroid ultrasound, 21–25
 Pheochromocytoma (PHEO), 158
 Postoperative anesthesia care unit (PACU), 71, 74
 Pretibial myxedema, 91, 94
 Prophylactic neck dissection, 170–172
 Prophylactic thyroidectomy, 159–160
 Propylthiouracil (PTU), 95
 Prostate-specific antigen (PSA), 134

Q

Quality-adjusted life-years (QALY), 101
 Quality of life, 224

R

Radiesse®, 117
 Radioactive iodine ablation (RAI), 91, 96–97, 178
 Radioactive iodine-resistant (RAI-R), 204
 Radioactive iodine uptake (RAIU), 205
 Radioiodine ablation, 203
 Radiological Society of North America (RSNA), 22
 Rapidly accelerated fibrosarcoma isoform B (BRAF), 144
 Recurrent laryngeal nerve (RLN), 29, 30, 40, 109, 112

- Recurrent laryngeal nerve injury, 76
- Remote access thyroid surgery
 considerations in, 85
 history of, 81–83
 rationale for, 81
- Restylane®, 118
- Robotic-assisted bilateral axillo-breast approach, 83–84
- Robotic-assisted transaxillary thyroidectomy (RAT), 83
- Robotic facelift thyroidectomy (RFT)
 availability, 87
 comparison of, 85
 incision for, 84
 indications and disease considerations, 87
 patient demand, 86
 reimbursement, 88
 resource utilization, 87–88
 robotic axillary thyroidectomy dissection pocket, 84
 safety, 85–86
 training and credentialing, 86–87
- Robotic thyroidectomy
 remote access thyroid surgery
 considerations in, 85
 history of, 81–83
 rationale for, 81
 robotic-assisted bilateral axillo-breast approach, 83–84
 robotic facelift thyroidectomy (RFT)
 availability, 87
 comparison of, 85
 incision for, 84
 indications and disease considerations, 87
 patient demand, 86
 reimbursement, 88
 resource utilization, 87–88
 robotic axillary thyroidectomy dissection
 pocket, 84
 safety, 85–86
 training and credentialing, 86–87
 robotic transaxillary thyroidectomy, 83
- Robotic transaxillary thyroidectomy, 83
- Romidepsin, 216
- S**
- Sorafenib, 204, 223
- Sternocleidomastoid (SCM), 164
- Superior laryngeal nerves (SLN), 39, 109, 112
- Surgeon volume, thyroid surgery
 and experience, 58–59
 patient outcomes
 by age, 59–63
 by race, 59
- Suspicious for follicular neoplasm or follicular neoplasm
 (SFN/FN), 8, 9, 143
- Suspicious for malignancy (SFM), 143
- T**
- Targeted therapies
 adjuvant treatments, 205–206
 cabozantinib, 211
 chemotherapy, 206–209
 controversial questions, 218–224
 lenvatinib, 214
 medullary and papillary thyroid cancers, molecular
 pathways of, 213
 mutational basis for, 209–210
 natural history of, 204
 phase III tyrosine kinase inhibitor, 212
 phase II trials in RAI-R DTC, 215
 prognosis, 204–205
 progression, 206
 quality of life, 224
 vandetanib, 210–211
- Teflon®, 117
- Thyroid cancer, 1447
 cross-sectional imaging
 computed tomography (CT), 190–191
 functional imaging, 191
 magnetic resonance imaging (MRI), 191
 imaging costs, 192
 lymph node metastases in, 138
 MACIS (metastases, age, completeness of resection,
 invasion, and size), 192
 neck ultrasound
 laryngeal ultrasonography, 189
 lymph nodes, 186–188
 previous neck surgery, setting of, 188
 primary tumors, 185–186
 ultrasound sonoelastography, 188–189
 preoperative and dynamic staging, 191–192
 radioactive iodine therapy, 190–191
 targeted therapies or nonsurgical treatment
 adjuvant treatments, 205–206
 cabozantinib, 211
 chemotherapy, 206–209
 controversial questions, 218–224
 lenvatinib, 214
 medullary and papillary thyroid cancers,
 molecular pathways of, 213
 mutational basis for, 209–210
 natural history of, 204
 phase III tyrosine kinase inhibitor, 212
 phase II trials in RAI-R DTC, 215
 prognosis, 204–205
 progression, 206
 quality of life, 224
 vandetanib, 210–211
- Thyroid Cancer Care Collaborative (TCCC), 21
- Thyroidectomy
 Graves' disease (GD), 97–99
 laryngeal examination
 asymptomatic vocal fold paralysis, 32
 feasibility of, 33–34
 larynx *vs.* subjective voice assessment, 30
 postoperative, 33
 preoperative, 32–33
 voice alteration, normal vocal fold mobility, 30–32
 laryngeal nerves, 31
 recurrent laryngeal nerve paralysis, prevalence of, 30
 transcuteaneous laryngeal ultrasonography (TLUSG), 35
- Thyroidectomy same day discharge, 67
- Thyroid gland, metastases to, 199–201

Thyroid lymphoma, 198–199
 Thyroid postoperative hematoma, 72
 Thyroid-stimulating hormone (TSH), 92, 128
 Thyroid surgery
 AGES (age, grade, extent, size), 59
 AMES (age, metastases, extent, size), 59
 changing patterns in, 63–64
 complications, 173
 and extent, 64
 surgeon volume
 and experience, 58–59
 patient outcomes, by age, 59–63
 patient outcomes, by race, 59
 surgical training and specialty, 63
 vocal fold paralysis, 116–118
 Thyroid ultrasound
 accreditation, 22–25
 detail-oriented and illustrated thyroid ultrasound
 report, 21
 fine-needle aspiration biopsy (FNA), 13
 indication for, 16
 pattern recognition, 21–25
 pocket-sized ultrasound devices, 14
 standardization of, 19, 21
 timing of, 19
 use of, 19, 21
 Transcutaneous laryngeal ultrasonography (TLUSG), 35
 Tumor node metastasis (TNM), 205
 Tyrosine kinase inhibitor, 209

U

Ultrasound. *See* Neck ultrasound; Thyroid ultrasound

V

Vandetanib, 221
 Vemurafenib, 216

VFP. *See* Vocal fold paralysis (VFP)
 VHI. *See* Voice Handicap Index (VHI)
 Vocal fold mobility, 30, 32
 Vocal fold paralysis (VFP), 30, 32, 34
 etiology of, 110
 incidence and prevalence, 109–111
 long-term management
 arytenoid adduction, 118–121
 laryngeal reinnervation, 120–121
 medialization laryngoplasty, 118–121
 management
 bilateral vocal fold paralysis, 121–122
 nerve intraoperatively, 114–116
 thyroid surgery, 116–118
 nerve injury during thyroidectomy,
 112–114
 voice and swallowing function, 111–112
 Voice Handicap Index (VHI), 32, 111, 117
 Volume-outcomes relationship, 57

W

Well-differentiated thyroid cancer (WDTC)
 biology of, 169–170
 clinical outcomes, 181
 continued risk stratification, 180–181
 incidence of, 127
 indications and outcomes, 172–173
 initial risk stratification, 177–178
 initial therapy response, 179–180
 initial treatment, 178–179
 prophylactic neck dissection, 170–172
 secondary risk stratification, 181, 182
 staging systems
 limitations of, 175–176
 risk stratification, 176
 surveillance, 181
 Wolff-Chaikoff effect, 101